Relmada Therapeutics (RLMD)
Develops NDV-01 for NMIBC and sepranolone for Prader-Willi syndrome.
$3.97
vs last close−0.28 (−6.49%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 94.68% | 101.00M shares | |
|---|---|---|---|
| 131 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.85% | 906.2K shares | |
| 2 holders · as of Nov 6, 2025 | |||
| Other | ≈ 4.47% | 4.76M shares | |
| remainder | |||
106.67M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
131 holders · 101.00M shares · 48 new positions · 85 increased · 22 reduced · 23 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Jupiter Topco LLC | 11.16M | 10.47% | +11.16Mnew | Aug 14, 2026 |
| BlackRock, Inc. | 7.43M | 6.96% | +6.14M | Aug 7, 2026 |
| Squadron Capital Management LLC | 7.35M | 6.89% | −1.12M | Aug 14, 2026 |
| VR Adviser, LLC | 6.84M | 6.42% | +2.00M | Aug 14, 2026 |
| Spruce Street Capital LP | 6.39M | 5.99% | +129.2K | Aug 13, 2026 |
| Adage Capital Partners GP, L.L.C. | 4.76M | 4.47% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.46M | 4.18% | +1.38M | Aug 13, 2026 |
| Jones Hill Capital LP | 3.66M | 3.43% | +3.31M | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Janus Henderson Group PLC | 10.10% | 7.44M | 13G | Feb 6, 2026 |
| Squadron Master Fund LP | 9.90% | 7.40M | 13G | Feb 17, 2026 |
| BlackRock, Inc. | 7.00% | 7.35M | 13G | Jul 29, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 6.20% | 6.51M | 13G | Jun 9, 2026 |
| Spruce Street Capital LP | 5.57% | 4.09M | 13G | Feb 17, 2026 |
| Commodore Capital LP | 5.10% | 5.51M | 13G | May 4, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 10, 2026 | Sergio Traversadirector, officer: Chief Executive Officer | Purchase | 100,000 | $4.10 | 1,500,000 |
| Sep 9, 2026 | Sergio Traversadirector, officer: Chief Executive Officer | Purchase | 100,000 | $4.18 | 1,400,000 |
| Sep 10, 2026 | Maged Shenoudaofficer: Chief Financial Officer | Purchase | 79,800 | $4.25 | 1,000,000 |
| Sep 9, 2026 | Maged Shenoudaofficer: Chief Financial Officer | Purchase | 120,200 | $4.20 | 920,200 |
| Dec 15, 2025 | Maged Shenoudaofficer: Chief Financial Officer | Purchase | 11,665 | $4.12 | 800,000 |
| Dec 15, 2025 | Sergio Traversadirector, officer: Chief Executive Officer | Purchase | 27,500 | $4.12 | 1,300,000 |
| Nov 5, 2025 | Paul Edward Kellydirector, officer: Chief Operating Officer | Purchase | 90,000 | $2.20 | 502,295 |
| Nov 5, 2025 | Sergio Traversadirector, officer: Chief Executive Officer | Purchase | 272,500 | $2.20 | 1,272,500 |
| Nov 5, 2025 | Chuck Enceofficer: CAO and COO | Purchase | 136,000 | $2.20 | 403,931 |
| Nov 5, 2025 | Maged Shenoudaofficer: Chief Financial Officer | Purchase | 500,000 | $2.20 | 788,335 |
House and Senate disclosures
Not reported.